
Conference Coverage
3 months ago
AOA 2026: Do researchers lie?Latest Content

AMA passes resolution backing formal disease classification for myopia

Managing MIGS: An optometrist’s practical comanagement guide

Takeaways from this week in optometry: September 7-11

UI researchers to advance potential antioxidant eye treatment with NIH funding award

FDA accepts Nanoscope's BLA for MCO-010 in retinitis pigmentosa

Shorts










Podcasts
Videos
Optometry Times Digital Edition







Continuing Medical Education
All News

Heru's PretestPro runs 4 pretesting exams in about 90 seconds on the Heru Prime wearable platform and reaches all current and future customers via free software update.

In the first episode of the second season of The Independent Advantage, Diana Canto-Sims, OD, chats with practice owner Maria Sampalis, OD, on why artificial intelligence has boomed in practice ownership spaces.

The latest in drug and technology developments and updates from August 2026.

Merabet, OD, PhD, MPH, discusses what his research on motion processing reveals about the neural roots of CVI and where diagnostic tools like neuroimaging and eye tracking are headed.

Host Hamza Shah, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension, inspired by Mitchell et al's paper, "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial."

Periocular skin treatment is emerging as a complementary treatment for dry eye disease.

Catch up on the top stories in optometry during the week of August 31-September 4.

SightGlass Vision reports the milestone just 1 year after reaching 1 million users.

The industry-sponsored survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Study: Tryptyr treatment associated with complex visual tasks improvement in DED patients
Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

The OTC lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

The evolution of IPL is not limited to its expanding role in ocular surface disease.

Catch up on the top stories in optometry during the week of August 24-28.

The findings extend prior Asian efficacy data to a diverse North American cohort for Stellest lenses.























